406 related articles for article (PubMed ID: 26429955)
21. Imaging of Prostate Cancer Using Urokinase-Type Plasminogen Activator Receptor PET.
Skovgaard D; Persson M; Kjaer A
PET Clin; 2017 Apr; 12(2):243-255. PubMed ID: 28267457
[TBL] [Abstract][Full Text] [Related]
22. Targeting VPAC1 Receptors for Imaging Glioblastoma.
Tripathi SK; Kean R; Bongiorno E; Hooper DC; Jin YY; Wickstrom E; McCue PA; Thakur ML
Mol Imaging Biol; 2020 Apr; 22(2):293-302. PubMed ID: 31292914
[TBL] [Abstract][Full Text] [Related]
23.
Vats K; Sharma R; Sarma HD; Satpati D; Dash A
Anticancer Agents Med Chem; 2018; 18(9):1289-1294. PubMed ID: 29546835
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic Value of Preoperative uPAR-PET/CT in Regional Lymph Node Staging of Oral and Oropharyngeal Squamous Cell Carcinoma: A Prospective Phase II Trial.
Lawaetz M; Christensen A; Juhl K; Lelkaitis G; Karnov K; Carlsen EA; Charabi BW; Loft A; Czyzewska D; Buchwald CV; Kjaer A
Diagnostics (Basel); 2023 Oct; 13(21):. PubMed ID: 37958201
[TBL] [Abstract][Full Text] [Related]
25. First-in-human uPAR PET: Imaging of Cancer Aggressiveness.
Persson M; Skovgaard D; Brandt-Larsen M; Christensen C; Madsen J; Nielsen CH; Thurison T; Klausen TL; Holm S; Loft A; Berthelsen AK; Ploug M; Pappot H; Brasso K; Kroman N; Højgaard L; Kjaer A
Theranostics; 2015; 5(12):1303-16. PubMed ID: 26516369
[TBL] [Abstract][Full Text] [Related]
26. Comparison of two new angiogenesis PET tracers 68Ga-NODAGA-E[c(RGDyK)]2 and (64)Cu-NODAGA-E[c(RGDyK)]2; in vivo imaging studies in human xenograft tumors.
Oxboel J; Brandt-Larsen M; Schjoeth-Eskesen C; Myschetzky R; El-Ali HH; Madsen J; Kjaer A
Nucl Med Biol; 2014 Mar; 41(3):259-67. PubMed ID: 24417983
[TBL] [Abstract][Full Text] [Related]
27. Urokinase-Type Plasminogen Activator Receptor (uPAR) PET/MRI of Prostate Cancer for Noninvasive Evaluation of Aggressiveness: Comparison with Gleason Score in a Prospective Phase 2 Clinical Trial.
Fosbøl MØ; Kurbegovic S; Johannesen HH; Røder MA; Hansen AE; Mortensen J; Loft A; Petersen PM; Madsen J; Brasso K; Kjaer A
J Nucl Med; 2021 Mar; 62(3):354-359. PubMed ID: 32764119
[TBL] [Abstract][Full Text] [Related]
28. MicroPET/CT imaging of patient-derived pancreatic cancer xenografts implanted subcutaneously or orthotopically in NOD-scid mice using (64)Cu-NOTA-panitumumab F(ab')2 fragments.
Boyle AJ; Cao PJ; Hedley DW; Sidhu SS; Winnik MA; Reilly RM
Nucl Med Biol; 2015 Feb; 42(2):71-7. PubMed ID: 25456837
[TBL] [Abstract][Full Text] [Related]
29. Imaging Tumor-Infiltrating Lymphocytes in Brain Tumors with [
Nagle VL; Henry KE; Hertz CAJ; Graham MS; Campos C; Parada LF; Pandit-Taskar N; Schietinger A; Mellinghoff IK; Lewis JS
Clin Cancer Res; 2021 Apr; 27(7):1958-1966. PubMed ID: 33495310
[TBL] [Abstract][Full Text] [Related]
30. ImmunoPET Imaging of CD146 in Murine Models of Intrapulmonary Metastasis of Non-Small Cell Lung Cancer.
England CG; Jiang D; Hernandez R; Sun H; Valdovinos HF; Ehlerding EB; Engle JW; Yang Y; Huang P; Cai W
Mol Pharm; 2017 Oct; 14(10):3239-3247. PubMed ID: 28825843
[TBL] [Abstract][Full Text] [Related]
31. uPAR-targeted optical near-infrared (NIR) fluorescence imaging and PET for image-guided surgery in head and neck cancer: proof-of-concept in orthotopic xenograft model.
Christensen A; Juhl K; Persson M; Charabi BW; Mortensen J; Kiss K; Lelkaitis G; Rubek N; von Buchwald C; Kjær A
Oncotarget; 2017 Feb; 8(9):15407-15419. PubMed ID: 28039488
[TBL] [Abstract][Full Text] [Related]
32. Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer.
Heskamp S; Laverman P; Rosik D; Boschetti F; van der Graaf WT; Oyen WJ; van Laarhoven HW; Tolmachev V; Boerman OC
J Nucl Med; 2012 Jan; 53(1):146-53. PubMed ID: 22173842
[TBL] [Abstract][Full Text] [Related]
33. Peptide-Based Optical uPAR Imaging for Surgery: In Vivo Testing of ICG-Glu-Glu-AE105.
Juhl K; Christensen A; Persson M; Ploug M; Kjaer A
PLoS One; 2016; 11(2):e0147428. PubMed ID: 26828431
[TBL] [Abstract][Full Text] [Related]
34. Correlation of Dynamic O-(2-[
Lohmann P; Piroth MD; Sellhaus B; Weis J; Geisler S; Oros-Peusquens AM; Mohlberg H; Amunts K; Shah NJ; Galldiks N; Langen KJ
World Neurosurg; 2018 Nov; 119():e653-e660. PubMed ID: 30077752
[TBL] [Abstract][Full Text] [Related]
35. Development of a New Folate-Derived Ga-68-Based PET Imaging Agent.
Brand C; Longo VA; Groaning M; Weber WA; Reiner T
Mol Imaging Biol; 2017 Oct; 19(5):754-761. PubMed ID: 28194631
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of prognostic integrin α2β1 PET tracer and concurrent targeting delivery using focused ultrasound for brain glioma detection.
Chung YH; Hsu PH; Huang CW; Hsieh WC; Huang FT; Chang WC; Chiu H; Hsu ST; Yen TC
Mol Pharm; 2014 Nov; 11(11):3904-14. PubMed ID: 25153169
[TBL] [Abstract][Full Text] [Related]
37. Preclinical Evaluation of [
Peng T; Wang X; Li Z; Bi L; Gao J; Yang M; Wang Y; Yao X; Shan H; Jin H
Mol Pharm; 2021 Sep; 18(9):3638-3648. PubMed ID: 34424706
[TBL] [Abstract][Full Text] [Related]
38. PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference.
Fani M; Del Pozzo L; Abiraj K; Mansi R; Tamma ML; Cescato R; Waser B; Weber WA; Reubi JC; Maecke HR
J Nucl Med; 2011 Jul; 52(7):1110-8. PubMed ID: 21680701
[TBL] [Abstract][Full Text] [Related]
39. Positron emission computed tomography targeting urokinase plasminogen activator receptor (uPAR) in cancer: a systematic review.
Camedda R; Frantellizzi V; Danieli R; De Vincentis G; Filippi L
Expert Rev Anticancer Ther; 2024; 24(3-4):137-145. PubMed ID: 38451196
[TBL] [Abstract][Full Text] [Related]
40. PET Imaging of Tissue Factor in Pancreatic Cancer Using 64Cu-Labeled Active Site-Inhibited Factor VII.
Nielsen CH; Jeppesen TE; Kristensen LK; Jensen MM; El Ali HH; Madsen J; Wiinberg B; Petersen LC; Kjaer A
J Nucl Med; 2016 Jul; 57(7):1112-9. PubMed ID: 27013699
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]